VRDN

Viridian Therapeutics, Inc. - Common Stock (VRDN)

About Viridian Therapeutics, Inc. - Common Stock (VRDN)

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Details

Daily high

$17.20

Daily low

$16.84

Price at open

$16.89

52 Week High

$27.20

52 Week Low

$9.90

Market cap

1.4B

Dividend yield

0.00%

Volume

187,214

Avg. volume

751,020

P/E ratio

-4.15

Viridian Therapeutics, Inc. - Common Stock News